Tony Abraham, DO, MPA, outlines the limitations of PSMA-PET imaging and discusses the importance of multidisciplinary care in overcoming challenges surrounding the interpretation and reporting of imaging results.
The PRESERVE trial is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation.
The drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.
"The durability response for these patients was impressive given the fact that these patients were those who, by definition and by inclusion criteria, were recurrent within a year at [baseline]," says Sandip M. Prasad, MD.
“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD.
"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Rebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
When a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.
“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.
“Before long, what we do, how we do it, and when we do it might solely be based off of those genetic testing results,” says Tim Richardson, MD.
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
“Black patients have over 2-fold excess mortality compared to White men, and that has been fairly consistent; the actual rate ratio has hovered between 2 and 2.5 for many years,” says Matthew R. Cooperberg, MD, MPH.
"Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
The AI tool outperformed MRI in assessing for SVI.
Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.
“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen.
Leading West Michigan practice now affiliated with nation’s largest urological healthcare management company
"I'm hopeful that the decisions are more informed in terms of actual science," says Daniel Kwon, MD.
The panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Recent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.
Here are seven ways texting can improve healthcare revenue and decrease costs.
"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
Independent health care practices rely on online ratings and reviews to attract new patients and establish themselves as leading, recognizable providers in their community.
While online reviews are critical in any industry, patient expectations are simply different when it comes to health care.
Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine.
"We need to be aware that patients have options for treatment of high-risk biochemical recurrence, and in order to identify that they have high-risk biochemical recurrence...we need to calculate PSA doubling time,” says Alicia Morgans, MD, MPH.